Reinhard Dummer

127.8k total citations · 15 hit papers
951 papers, 44.0k citations indexed

About

Reinhard Dummer is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Reinhard Dummer has authored 951 papers receiving a total of 44.0k indexed citations (citations by other indexed papers that have themselves been cited), including 503 papers in Oncology, 438 papers in Molecular Biology and 281 papers in Dermatology. Recurrent topics in Reinhard Dummer's work include Melanoma and MAPK Pathways (284 papers), Cutaneous lymphoproliferative disorders research (202 papers) and CAR-T cell therapy research (201 papers). Reinhard Dummer is often cited by papers focused on Melanoma and MAPK Pathways (284 papers), Cutaneous lymphoproliferative disorders research (202 papers) and CAR-T cell therapy research (201 papers). Reinhard Dummer collaborates with scholars based in Switzerland, Germany and United States. Reinhard Dummer's co-authors include Günter Burg, Dirk Schadendorf, Axel Hauschild, Frank O. Nestlé, Michel Gilliet, Caroline Robert, Mirjana Urosevic, Paolo A. Ascierto, Selma Alijagic and Yuansheng Sun and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Reinhard Dummer

927 papers receiving 43.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 2.4k citations Michel Gilliet, Reinhard Dummer et al. profile →
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Reinhard Dummer, Olivier Michielin et al. profile →
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Caroline Robert, Peter Hersey et al. profile →
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. profile →
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

2007 926 citations Reinhard Dummer, Günter Burg et al. profile →
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Reinhard Dummer et al. profile →
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
The Genetic Evolution of Melanoma from Precursor Lesions

2015 660 citations Reinhard Dummer, Boris C. Bastian et al. profile →
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2012 582 citations Reinhard Dummer, Axel Hauschild et al. profile →
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

2013 539 citations William R. Sellers, Mitchell P. Levesque et al. profile →
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

2008 523 citations Reinhard Dummer et al. Cancer Research profile →
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

2013 499 citations Paolo A. Ascierto, Dirk Schadendorf et al. profile →
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2019 405 citations Olivier Michielin, Paolo A. Ascierto et al. profile →
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. profile →
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

2015 284 citations Reinhard Dummer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reinhard Dummer Switzerland	100	22.4k	19.1k	14.7k	8.5k	6.5k	951	44.0k
Claus Garbe Germany	93	21.3k 1.0×	15.0k 0.8×	7.0k 0.5×	6.3k 0.7×	6.3k 1.0×	750	34.4k
Martín C. Mihm United States	94	20.4k 0.9×	9.2k 0.5×	8.2k 0.6×	7.7k 0.9×	5.4k 0.8×	456	34.5k
Dirk Schadendorf Germany	101	27.6k 1.2×	21.3k 1.1×	15.5k 1.1×	2.5k 0.3×	3.5k 0.5×	982	46.5k
John M. Kirkwood United States	104	31.3k 1.4×	17.9k 0.9×	18.8k 1.3×	2.3k 0.3×	4.8k 0.7×	687	46.4k
Merrick I. Ross United States	90	24.6k 1.1×	8.2k 0.4×	5.4k 0.4×	4.2k 0.5×	7.3k 1.1×	425	34.7k
Richard A. Scolyer Australia	84	21.3k 1.0×	13.3k 0.7×	6.6k 0.5×	2.7k 0.3×	4.1k 0.6×	707	30.6k
Donald L. Morton United States	86	22.7k 1.0×	10.4k 0.5×	8.8k 0.6×	3.0k 0.4×	6.8k 1.0×	448	33.4k
Elaine S. Jaffe United States	122	28.2k 1.3×	8.6k 0.5×	15.2k 1.0×	7.7k 0.9×	5.5k 0.8×	720	63.1k
Warren J. Leonard United States	114	13.5k 0.6×	8.2k 0.4×	31.8k 2.2×	2.4k 0.3×	2.7k 0.4×	333	45.6k
Frédéric J. de Sauvage United States	86	8.0k 0.4×	17.7k 0.9×	6.5k 0.4×	1.8k 0.2×	1.8k 0.3×	148	31.0k

Countries citing papers authored by Reinhard Dummer

Since Specialization

Citations

This map shows the geographic impact of Reinhard Dummer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reinhard Dummer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reinhard Dummer more than expected).

Fields of papers citing papers by Reinhard Dummer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reinhard Dummer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reinhard Dummer. The network helps show where Reinhard Dummer may publish in the future.

Co-authorship network of co-authors of Reinhard Dummer

This figure shows the co-authorship network connecting the top 25 collaborators of Reinhard Dummer. A scholar is included among the top collaborators of Reinhard Dummer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reinhard Dummer. Reinhard Dummer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mangana, Joanna, Berna C. Özdemir, Daniela Mihic‐Probst, et al.. (2025). The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly. 155(7). 4210–4210.

Ascierto, Paolo A., Sonia Dolfi, Marta Nyakas, et al.. (2025). Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. Journal for ImmunoTherapy of Cancer. 13(2). e009773–e009773. 1 indexed citations

Schadendorf, Dirk, Jason J. Luke, Paolo A. Ascierto, et al.. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer. 12(3). e007501–e007501. 5 indexed citations

Gómez, Julia M. Martínez, Patrick Turko, Egle Ramelyte, et al.. (2024). Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. Cancers. 16(5). 854–854. 2 indexed citations

Joshua, Anthony M., et al.. (2023). Chemotherapy in Cutaneous Melanoma: Is There Still a Role?. Current Oncology Reports. 25(6). 609–621. 32 indexed citations

Ramelyte, Egle, Mirjam Nägeli, Robert E. Hunger, et al.. (2022). Swiss Recommendations for Cutaneous Basal Cell Carcinoma. Dermatology. 239(1). 122–131. 6 indexed citations

Migden, Michael R., et al.. (2021). A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. Journal of Drugs in Dermatology. 20(2). 156–165. 27 indexed citations

Kempf, Werner, Joanna Mangana, Phil F. Cheng, et al.. (2020). The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma. Histopathology. 77(3). 460–470. 16 indexed citations

Basler, Lucas, Hubert S. Gabryś, Sabrina A. Hogan, et al.. (2020). Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research. 26(16). 4414–4425. 69 indexed citations

10.

Freiberger, Sandra N., Grégoire B. Morand, Patrick Turko, et al.. (2019). Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. Cancers. 11(9). 1329–1329. 11 indexed citations

11.

Dimitriou, Florentia, A.L. Frauchiger, Mirjana Urosevic‐Maiwald, et al.. (2018). Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Research. 28(3). 230–236. 61 indexed citations

12.

Koelblinger, Peter, et al.. (2017). A review of binimetinib for the treatment of mutant cutaneous melanoma. Future Oncology. 13(20). 1755–1766. 40 indexed citations

13.

Freiberger, Sandra N., Phil F. Cheng, Piotr Dziunycz, et al.. (2015). Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 14(9). 2132–2142. 35 indexed citations

14.

McCusker, Margaret, Nicole Basset‐Séguin, Reinhard Dummer, et al.. (2014). Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer. 50(4). 774–783. 139 indexed citations

15.

Cronin, Julia C., Dawn E. Watkins‐Chow, Nicola Schönewolf, et al.. (2013). SOX10 Ablation Arrests Cell Cycle, Induces Senescence, and Suppresses Melanomagenesis. Cancer Research. 73(18). 5709–5718. 68 indexed citations

16.

Kirkwood, John M., Lars Bastholt, Caroline Robert, et al.. (2011). Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical Cancer Research. 18(2). 555–567. 218 indexed citations

17.

Conzett, Katrin Baumann, Marie Zipser, Valérie Enderlin, et al.. (2010). Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders. Clinical Cancer Research. 16(3). 1058–1064. 49 indexed citations

18.

Lin, William M., Alissa C. Baker, Rameen Beroukhim, et al.. (2008). Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma. Cancer Research. 68(3). 664–673. 215 indexed citations

19.

Urosevic, Mirjana, Reinhard Dummer, Curdin Conrad, et al.. (2005). Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment. JNCI Journal of the National Cancer Institute. 97(15). 1143–1153. 141 indexed citations

20.

Urosevic, Mirjana, Tanja Maier, Bernd Benninghoff, et al.. (2003). Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo. Archives of Dermatology. 139(10). 1325–32. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact